Cambium Bio Advances Dry Eye Treatment with Dual Ethics Approvals for Phase 3 Trials

middle.news 9:32am on Monday 30th of June, 2025 AEST • Healthcare Read Story

Cambium Bio Advances Dry Eye Treatment with Dual Ethics Approvals for Phase 3 Trials

9:32am on Monday 30th of June, 2025 AEST Key Points Ethics approvals granted by Bellberry HREC (Australia) and Advarra IRB (US) Phase 3 trials to enrol approximately 800 patients globally First patient dosing anticipated in October 2025 Top-line data expected in Q3 2026 Read Story

middle. Tap to Read Tap the card to read the full analysis about CMB OPEN ARTICLE